Clinical Trial Update: The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy. [Phase 2]

View source ↗

Summary

Phase 2 trial completed assessing rosiglitazone for ischemia-reperfusion injury using Annexin A5 scintigraphy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemia-reperfusion Injury
• Metabolic Syndrome

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Ischemia-Reperfusion Injury, The Metabolic Syndrome | Phase 2 | Status: COMPLETED